Spago Nanomedical Q3: All eyes of Tumorad - Redeye

Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is recruiting the next patient cohort on the two active sites after securing the go-ahead from the DMC committee during the quarter. The future OPEX base will reflect the post-Q3 strategic decision to focus on the Tumorad development program with all available resources.

Länk till analysen i sin helhet: https://www.redeye.se/research/1052333/spago-nanomedical-q3-all-eyes-of-tumorad?utm_source=finwire&utm_medium=RSS